Based on the knowledge of oxidative stress and uric acid, Freeox Biotech is developing neuroprotective therapies to reduce the damage resulting from ischemia and in this way improve the recovery of the patients.
Currently FreeOx has two products in its pipeline:
Ox-01 is Uric Acid used as a medicinal product. Ox-01 has a proven effect in preventing the damage caused by reperfusion after stroke. Among its multiple direct antioxidant actions, it is able to scavenge hydroxyl radicals and hydrogen peroxide, suppress the Fenton reaction, chelate transition metals and prevent lipid peroxidation. Also scavenges free radicals such as hydroxyl radicals, hydrogen peroxide and the radicals formed by the decomposition of peroxynitrite. And it also prevents the degradation of extracellular SOD3, an enzyme critical in maintaining normal endothelial and vascular function.
Freeox Biotech has completed clinical trials with Ox-01 until phase IIb (421 patients) demonstrating good safety and tolerance profile, and statistically significant efficacy as a neuroprotectant in stroke in some patient subgroups such as women, hyperglycaemic patients and patients undergoing mechanical thrombectomy. No other product has achieved to demonstrate neuroprotectant properties
Ox-02; Uricoline is a molecule resulting from the association of Ox-01 and Citicoline. Citicoline is an intermediate in the generation of phosphatidylcholine from choline, a common biochemical process in cell membranes. Citicoline is naturally occurring in the cells of human and animal tissue. Uricoline is in the early stages of preclinical development.